







### ADVANCED PROSTATE CANCER **CONSENSUS CONFERENCE**

St.Gallen / Switzerland 12 – 14 March 2015

# Advanced Prostate Cancer Consensus Conference (APCCC)

## St. Gallen / Switzerland

SAVE THE DATE: 12 -14 March 2015



#### www.prostatecancerconsensus.org

#### The Advanced Prostate Cancer Consensus Conference APCCC will:

- Provide an update on the current standard of advanced prostate cancer management.
- Program will be highly educational, consisting of invited lectures, debates and discussions led by the panel of international and interdisciplinary prostate cancer experts.
- The conference will culminate on Saturday with an interdisciplinary expert consensus panel meeting that will discuss and vote on predefined questions relating to key areas where there is lack of evidence or conflict regarding the optimal treatment of men with advanced prostate cancer. Participants will be able to attend the panel meeting as part of the conference.
- The consensus summary will be submitted for publication after the meeting in a high impact medical
- Attendees will be able to interact with panel members, facilitating and encouraging international collaboration.

#### **Consensus Expert Panel**

Attard G, UK Beltran H, US Chi K, Canada Chinnaiyan A, US Daugaard G, Denmark Davis I, Australia De Bono J, UK De Santis M, Austria Drake C, US Eeles R, UK Efstathiou E, Greece/US Fanti S, Italy

Fizazi K, France

Gillessen S, Switzerland

Gleave M, Canada Halabi S, US Heidenreich A, Germany Hussain M, US James N, UK Lecouvet B, Belgium Logothetis C, US Nelson P, US Nilsson S, Sweden Oh W, US Olmos D, Spain Padhani A, UK Parker C, UK

Ryan C, US Sartor O, US Schalken J, Holland Scher H, US Sella A, Israel Shore N, US Small E, US Smith M, US Soule H, US (Scientific Committee) Sternberg C, Italy Suzuki H Japan Tannock I, Canada

Tombal B, Belgium

Endorsement (will be updated)

ESO recommended:








Rubin M, US











krebsforschung schweiz recherche suisse contre le canc ricerca svizzera contro il canc swiss cancer research











# ADVANCED PROSTATE CANCER CONSENSUS CONFERENCE

St.Gallen / Switzerland 12 – 14 March 2015

Thursday 12 March 2015 10am-6pm	
	Current treatment options: State of the Art
Session 1	Role of new endocrine agents in advanced prostate cancer (APC)
	Role of chemotherapy in the management of APC?
	Role of immunotherapies in APC
	Bone metastases: Best management strategies
Session 2	How to best prevent skeletal related events (SRE's) in the era of novel
	treatment options?
	How to make best use of radium223?
	Early detection and treatment of patients with malignant spinal cord
	compression
Coopies 2	Debates: The role of "vintage" hormonal manipulations
Session 3	At progression after ADT: Is a "vintage" androgen receptor inhibitor     At progression after ADT: Is a "vintage" androgen receptor inhibitor
	useful?
	Single agent steroids: "Dead or Alive"?      Keteenparder "Dead or Alive"?
	Ketoconazole: "Dead or Alive"?  Fetrogene: "Dead or Alive"?
	Estrogens: "Dead or Alive"?  Management of appoint APC clinical situations
Session 4	Management of special APC clinical situations
3ession 4	Management of local complications in APC     When to use redicther any in APC
	When to use radiotherapy in APC     Small and application prostate concern
	Small cell and anaplastic prostate cancer     Meningeal carcinomatosis and brain metastases
	<ul> <li>Meningeal carcinomatosis and brain metastases</li> <li>Management of young (&lt;55) and old (&gt;85) and/or frail patients</li> </ul>
	Patients with DIC and bone marrow failure
Friday 13 March 2015 8am-6.30pm  Management of hormone sensitive metastatic prostate cancer	
Session 5	Intermittent versus continuous ADT
Jession 3	
	Bone targeting agents in hormone sensitive metastatic prostate cancer  What's the role of deserting in the management of hormone agentitive
	<ul> <li>What's the role of docetaxel in the management of hormone sensitive metastatic prostate cancer?</li> </ul>
-	Molecular characterisation of APC – Relevance today
Session 6	<ul> <li>Androgen receptor and other steroid receptors: the key drivers of APC?</li> </ul>
00331011 0	Mechanisms of resistance to ADT and how this informs us clinically
	Current state of molecular characterisation of prostate cancer
	Serum based biomarkers and CTCs
	Patients with BRCA1/2 and other germline mutations
	M0 CRPC – an overview and debate
Session 7	What imaging and when in M0 CRPC?
	What treatments are recommended for M0 CRPC?
	Debate: Novel survival prolonging treatments for M0 CRPC?
	Monitoring of Disease Activity: a challenging task
Session 8	Current imaging for APC – an unsolved daily clinical problem: the
	radiologists view
	Current imaging for APC – an unsolved daily clinical problem: the nuclear
	medicine view
	Prostate Cancer Working Group criteria – what's the next generation?
	When to change treatment for APC patients in daily practice
	How to transfer trial results into clinical practice?
Session 9	Interpretation of trial results
	Treatment decisions: Quality of life is important
	Combination strategies: Is more better?
	Sequencing Strategies: How to select the best sequence?
	Shift from prognostication to prediction in APC: are we ready?
Session 10	Debate: Abiraterone acetate or enzalutamide as first-line treatment
	<b>Debate:</b> Chemotherapy before use of survival prolonging novel endocrine
agents	
Saturday 14 <sup>th</sup> of March 2015 9am-1pm	

Consensus Panel – Discussion and votes on consensus questions (open to participants)